MedTrace Logo

Artificial Intelligence Models for Precision Prediction and Treatment of Prostate Cancer

NCT06662708 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2024-10-29

No results posted yet for this study

Summary

The aim of this clinical trial is whether artificial intelligence models can be used for accurate clinical preoperative diagnosis and postoperative diagnosis of pathological findings, and will also measure the accuracy of the predictions made by the artificial intelligence models.The main target questions addressed by the model building are:

1. whether the AI model can learn from preoperative MRI and postoperative Whole Slide Images so as to accurately predict information such as benignness or malignancy, aggressiveness, grading, subtypes, genes, etc. for participants suspected of having prostate cancer preoperatively/puncturally.
2. whether the AI model is capable of learning postoperative macropathology slides to enable outcome diagnosis of surgical pathology slides in new participants.

Participants will:

1. complete an MRI examination and have their MRI images analysed by the established AI model to make an accurate diagnosis of them.
2. Based on the diagnosis, if prostate cancer is predicted, they will undergo radical prostate cancer surgery and refine their surgical pathology.

Conditions

  • Prostate Cancer
  • Prostate Intraductal Carcinoma
  • Prostate Cancer Aggressiveness
  • Prostate Cancer Stage
  • Pathology

Interventions

DIAGNOSTIC_TEST

Accurate Prediction Artificial Intelligence Models

Diagnostic Test: Accurate Prediction Artificial Intelligence Models Post-operative pathology, precise pre-operative diagnosis (including benign and malignant, invasive, grading, subtypes) or 3D lesion modelling will be predicted based on the AI predictive model in response to the information provided

Sponsors & Collaborators

  • Institute of Automation, Chinese Academy of Sciences

    collaborator OTHER

  • Shao Pengfei

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-12-01
Primary Completion
2030-01-01
Completion
2030-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06662708 on ClinicalTrials.gov